Status:
NOT_YET_RECRUITING
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
Lead Sponsor:
Peking University People's Hospital
Conditions:
CLL
Eligibility:
All Genders
18+ years
Brief Summary
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients aged ≥18 years old
- Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \[International Workshop on Chronic Lymphocytic Leukemia\] criteria)；
- Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on BTK inhibitor;
- Prior or current use of BTK inhibitor for ≥3 months
- At least one follow-up was recorded during BTK inhibitor treatment
Exclusion
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06557304
Start Date
September 1 2024
End Date
December 30 2027
Last Update
August 21 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.